Discover why Hims & Hers Health is a top telehealth leader with impressive growth potential and a promising future for ...

Andrew Dudum, CEO of Hims & Hers Health Inc. (NYSE:HIMS), recently sold a significant portion of his holdings in the company.

Hims & Hers Health ( HIMS 6.30%) is coming off a fantastic year in 2024 when its share price skyrocketed 172%. The telehealth ...

Hims & Hers Health, Inc. (HIMS) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Financial writer highlights undervalued Hims & Hers Health with impressive growth potential and innovative product launches, ...

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

Hims & Hers reported impressive third-quarter results in November, with earnings of 32 cents per share, far exceeding analyst ...

Welcome to this week’s installment of “The Short Interest Report” – The Fly’s weekly recap of short interest trends among some of the most ...

Hims & Hers (HIMS) is down -6.5%, or -$1.81 to $26.13.Stay Ahead of the Market:Discover outperforming stocks and invest smarter with Top ...